secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038728
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400
--------------------------------------------------------------------------------

- Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.
- Cash $11.1M as of Dec 31, 2024; plus $4.1M net proceeds from ATM/warrant exercises in Feb 2025, extending runway into March 2026.
- INB-100 Phase 1: 100% of treated AML patients relapse-free as of Jan 17, 2025; no CRS/ICANS; enrollment expansion ongoing.
- INB-200: majority of patients exceeded expected PFS; one IDH-mutant patient progression-free for 40.5 months as of Oct 2024.
- INB-400 Phase 2 enrollment paused; seeking partnerships; introduced INB-600 platform (INB-619 TCE targeting CD19) with preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/0000950170-25-038728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/inab-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer